RecruitingNCT06641362

Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

Pivotal Clinical Study of VDI's Ultra-High Frequency Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED): THE SYNC Study


Sponsor

VDI Technologies

Enrollment

360 participants

Start Date

Mar 18, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to demonstrate the safety and effectiveness of the VDI UHF-ECG System in the diagnosis of ventricular dyssynchrony when compared to the 12-lead ECG in patients with bradycardia and heart failure indicated for pacemaker implantation.


Eligibility

Min Age: 18 Years

Inclusion Criteria8

  • Adults with bradycardia scheduled for pacemaker implant or heart failure patients indicated for cardiac resynchronization therapy (CRT) with one of the following:
  • Bradycardia with ventricular synchrony and QRS duration \< 110 ms in men or \< 100 ms in women or;
  • Bradycardia with left bundle branch block and QRS duration \> 140 ms in men or \> 130 ms in women or;
  • Bradycardia with right bundle branch block and QRS duration \> 130 ms in men or \> 120 ms in women or;
  • Heart failure with left bundle branch block and QRS duration \> 140 ms in men or \>130 ms in women.
  • Understands the nature of the study and is willing to comply with all study requirements.
  • Provides written informed consent.
  • A negative pregnancy test prior to the procedure for participants of child-bearing potential.

Exclusion Criteria5

  • Complete AV block (3rd-degree AV block) without a stable escape rhythm or other circumstances where there is no measurable QRS.
  • Subjects with a previous or current pacemaker or defibrillator implant.
  • Anatomical or other conditions that may make a 12-lead ECG difficult to obtain, such as an allergy to components of the ECG pads, burns, open wounds, etc.
  • Currently enrolled in another investigational device or drug trial that has not completed the active treatment phase and/or would conflict with this study.
  • Other co-morbid condition(s) that could limit the participant's ability to participate in the study or to comply with study requirements or impact the scientific integrity of the study.

Interventions

DEVICEUltra High Frequency Electrocardiogram (UHF-ECG)

Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.


Locations(9)

Peak Heart and Vascular

Avondale, Arizona, United States

Banner Medical Center

Mesa, Arizona, United States

University of Chicago

Chicago, Illinois, United States

Mayo Clinic

Rochester, Minnesota, United States

Ohio State University

Columbus, Ohio, United States

Baylor College of Medicine

Houston, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

St. Anne's University Hospital

Brno, Czechia

Catherina Ziekenhuis

Eindhoven, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06641362


Related Trials